Knockdown of lncRNA ACTA2-AS1 reverses cisplatin resistance of ovarian cancer cells via inhibition of miR-378a-3p-regulated Wnt5a

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Clamp AR, James EC, McNeish IA, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet. 2019;394(10214):2084–2095.
   PubMed Web of Science ®Google Scholar
• Dall’Acqua A, Sonego M, Pellizzari I, et al. CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation. EMBO Mol Med. 2017;9(10):1415–1433.
   PubMed Web of Science ®Google Scholar
• Louro R, Smirnova AS, Verjovski-Almeida S. Long intronic noncoding RNA transcription: expression noise or expression choice? Genomics. 2009;93(4):291–298.
   PubMed Web of Science ®Google Scholar
• Loewer S, Cabili MN, Guttman M, et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet. 2010;42(12):1113–1117.
   PubMed Web of Science ®Google Scholar
• Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 2009;23(13):1494–1504.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang YX, Wang DL, et al. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network. Theranostics. 2020;10(23):10823–10837.
   PubMed Web of Science ®Google Scholar
• Yuan J, Song Y, Pan W, et al. LncRNA SLC26A4-AS1 suppresses the MRN complex-mediated DNA repair signaling and thyroid cancer metastasis by destabilizing DDX5. Oncogene. 2020;39(43):6664–6676.
   PubMed Web of Science ®Google Scholar
• Fan Y, Sheng W, Meng Y, et al. LncRNA PTENP1 inhibits cervical cancer progression by suppressing miR-106b. Artif Cells Nanomed Biotechnol. 2020;48(1):393–407.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Hong L. lncRNA-PRLB confers paclitaxel resistance of ovarian cancer cells by regulating RSF1/NF-kappaB signaling pathway. Cancer Biother Radiopharm. 2021;36(2):202–210.
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang T, Xia L, et al. LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis. Cancer Cell Int. 2021;21(1):284.
   PubMed Web of Science ®Google Scholar
• Li Y, Yang Z, Chen J. Mechanism underlying the regulation of lncRNA ACTA2-AS1 on CXCL2 by absorbing miRNA-532-5p as ceRNA in the development of ovarian cancer. Int J Clin Exp Pathol. 2021;14(5):596–607.
   PubMed Web of Science ®Google Scholar
• Luo L, Wang M, Li X, et al. A novel mechanism by which ACTA2-AS1 promotes cervical cancer progression: acting as a ceRNA of miR-143-3p to regulate SMAD3 expression. Cancer Cell Int. 2020;20(1):372.
   PubMed Web of Science ®Google Scholar
• Qiao XL, Zhong ZL, Dong Y, et al. LncRNA HMGA1P4 promotes cisplatin-resistance in gastric cancer. Eur Rev Med Pharmacol Sci. 2020;24(17):8830–8836.
   PubMed Web of Science ®Google Scholar
• Zhang F, Wang H, Yu J, et al. LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM. Mol Cancer. 2021;20(1):6.
   PubMed Web of Science ®Google Scholar
• Shi Q, Li Y, Li S, et al. LncRNA DILA1 inhibits cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer. Nat Commun. 2020;11(1):5513.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang J, Dong L, et al. LncRNA ATXN8OS enhances tamoxifen resistance in breast cancer. Open Med (Wars). 2021;16(1):68–80.
   PubMedGoogle Scholar
• Zhou C, Yi C, Yi Y, et al. LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/beta-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes. Mol Cancer. 2020;19(1):118.
   PubMed Web of Science ®Google Scholar
• Lin Z, Lu S, Xie X, et al. Noncoding RNAs in drug-resistant pancreatic cancer: a review. Biomed Pharmacother. 2020;131:110768.
   PubMed Web of Science ®Google Scholar
• Zhu J, Fu H, Wu Y, et al. Function of lncRNAs and approaches to lncRNA-protein interactions. Sci China Life Sci. 2013;56(10):876–885.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Sun W, Guo Z, et al. Mechanisms of lncRNA/microRNA interactions in angiogenesis. Life Sci. 2020;254:116900.
   PubMed Web of Science ®Google Scholar
• Statello L, Guo CJ, Chen LL, et al. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96–118.
   PubMed Web of Science ®Google Scholar
• Zhu M, Yang L, Wang X. NEAT1 Knockdown Suppresses the Cisplatin Resistance in Ovarian Cancer by Regulating miR-770-5p/PARP1 Axis. Cancer Manag Res. 2020;12:7277–7289.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang X, Han L, et al. LncRNA MALAT1 regulates the progression and cisplatin resistance of ovarian cancer cells via modulating miR-1271-5p/E2F5 axis. Cancer Manag Res. 2020;12:9999–10010.
   PubMed Web of Science ®Google Scholar
• Xu ZH, Yao TZ, Liu W. miR-378a-3p sensitizes ovarian cancer cells to cisplatin through targeting MAPK1/GRB2. Biomed Pharmacother. 2018;107:1410–1417.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Horie-Inoue K, Ueno T, et al. miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A. Sci Rep. 2015;5(1):13170.
   PubMed Web of Science ®Google Scholar
• Lin Z, Xia S, Liang Y, et al. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription. Theranostics. 2020;10(19):8834–8850.
   PubMed Web of Science ®Google Scholar
• Yang J, Zhang K, Wu J, et al. Wnt5a increases properties of lung cancer stem cells and resistance to cisplatin through activation of Wnt5a/PKC signaling pathway. Stem Cells Int. 2016;2016:1690896.
   PubMed Web of Science ®Google Scholar
• Gu ZW, He YF, Wang WJ, et al. 骨髓间充质干细胞释放miR-1180 上调Wnt 信号 通路活性并促进卵巢癌细胞糖酵解和化疗耐药 能力的研究. J Zhejiang Univ Sci B. 2019;20(3):219–237.
   PubMed Web of Science ®Google Scholar